Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials.
作者信息
Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Karanam Dhatri, Kuppermann Baruch D, Bandello Francesco, Regillo Carl D
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Madhavi Netralaya, Ara, Bihar, India.
出版信息
Eye (Lond). 2022 Apr;36(4):679-680. doi: 10.1038/s41433-021-01831-4. Epub 2021 Oct 30.
Abstract
摘要
相似文献
1
Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials.法西单抗3期糖尿病性黄斑水肿试验个性化治疗间隔（PTI）方案对未来糖尿病性黄斑水肿试验的意义
Eye (Lond). 2022 Apr;36(4):679-680. doi: 10.1038/s41433-021-01831-4. Epub 2021 Oct 30.
2
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.贝伐珠单抗联合雷珠单抗治疗糖尿病黄斑水肿的多中心、随机、双盲、假手术对照 2 期临床试验
Ophthalmology. 2019 Aug;126(8):1155-1170. doi: 10.1016/j.ophtha.2019.03.023. Epub 2019 Mar 21.
3
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.约塞米蒂和莱茵河：法西单抗治疗糖尿病性黄斑水肿的3期随机临床试验：研究设计与原理
Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar.
4
Faricimab: First Approval.法西单抗：首次获批。
Drugs. 2022 May;82(7):825-830. doi: 10.1007/s40265-022-01713-3.
5
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.法替西单抗：一种针对 Tie-2/血管生成素途径和 VEGF-A 的研究性药物，用于治疗视网膜疾病。
Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. doi: 10.1080/13543784.2021.1879791. Epub 2021 Feb 4.
6
The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.微脉冲激光联合雷珠单抗治疗糖尿病黄斑水肿的疗效：一项随机对照试验的研究方案。
Trials. 2022 Sep 2;23(1):736. doi: 10.1186/s13063-022-06593-2.
7
VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.糖尿病性黄斑水肿患者中VEGF-A基因多态性与玻璃体内注射雷珠单抗治疗的反应
Int Ophthalmol. 2018 Dec;38(6):2381-2388. doi: 10.1007/s10792-017-0738-5. Epub 2017 Oct 13.
8
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.雷珠单抗治疗年龄相关性黄斑变性和糖尿病性黄斑水肿的长期疗效。
Clin Interv Aging. 2013;8:467-83. doi: 10.2147/CIA.S36811. Epub 2013 Apr 29.
9
Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.雷珠单抗0.5毫克治疗糖尿病性黄斑水肿所致视力损害患者的真实世界转归：36个月BOREAL-DME研究的12个月结果
Ophthalmic Res. 2019;62(2):101-110. doi: 10.1159/000497406. Epub 2019 Mar 29.
10
Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.利用患者层面的数据进行糖尿病性黄斑水肿患者视力损害的有意义的跨试验比较。
Adv Ther. 2016 Apr;33(4):597-609. doi: 10.1007/s12325-016-0310-0. Epub 2016 Mar 7.
引用本文的文献
1
Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations.从当前的抗血管内皮生长因子（VEGF）疗法转换为法西单抗：基于证据的专家建议。
BMJ Open Ophthalmol. 2025 Jan 16;10(1):e001967. doi: 10.1136/bmjophth-2024-001967.
2
Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy.用于糖尿病性视网膜病变抗血管生成治疗的最佳人源化 Scg3 中和抗体。
Int J Mol Sci. 2024 Sep 1;25(17):9507. doi: 10.3390/ijms25179507.
3
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials.法西单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿的疗效、持久性和安全性：注册试验的经验教训。
Ophthalmol Ther. 2023 Oct;12(5):2253-2264. doi: 10.1007/s40123-023-00753-6. Epub 2023 Jul 6.
4
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.经工程改造以识别效应子沉默的肿瘤抗原靶向人 IgG1 抗体的 P329G 突变 Fc 部分的嵌合抗原受体 T 细胞可实现对实体瘤的模块化靶向。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-005054.
Zotero 插件